HOUSTON, March 22, 2016 /PRNewswire/ -- Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with BioCore Co. Ltd., a leading bioanalytical contract research organization, based in Seoul, South Korea. BioCore has an established reputation for quality service and a customer base that extends throughout Asia. This partnership expands BioCore's portfolio, adding Diversigen's advanced microbiome/metagenomics analysis to BioCore's extensive laboratory service offerings, and facilitates Diversigen's entry into the rapidly growing Asian pharmaceutical market.
"BioCore offers the best in a strategic partner – deep domain expertise, a solid reputation, and an innovative approach to serving their customers," said Dr. Caroline Popper, CEO of Diversigen. "We look forward to helping BioCore and their customers gain competitive advantage through solutions designed to accelerate and transform discovery research, accelerate otherwise lengthy clinical trials, and capitalize on the diverse opportunities of the microbiome."
Mr. H.S. Choie, President and CEO of BioCore said, "Our partnership with Diversigen gives BioCore an opportunity to broaden our reach in the Korean pharmaceutical market and provide our customers with access to the leading scientists in the exploding field of microbiome research."
Diversigen provides comprehensive microbiome/metagenomic and host genetic services, including customized and complex data analysis, focused on solutions to improve human and animal health, environmental conditions, and agriculture production worldwide. The company is a BCM Technologies, Inc. portfolio company. Building on research conducted at the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine, Diversigen has years of experience, flexible sequencing and massive bioinformatics capacity with highly diverse microbiome sample types. For more information, visit www.diversigen.com.
BioCore is South Korea's largest provider of bioanalytical liquid chromatography-tandem mass spectrometry (LC/MS/MS) services. BioCore was South Korea's first GLP-compliant centralized bioanalytical CRO in 2005, and the first to be certified by the Korea Food and Drug Administration as a Bioequivalence Testing Institution in 2008. As the exclusive partnership with Quintiles in Asia's PK bioanalytical analysis area since 2012, BioCore provides accurate and reliable analysis services. BioCore has expanded its suite of capabilities under the BioCore Research Arm of the business which includes a global provider of microtrace solutions (Low 14C bioanalysis using Accelerator Mass Spectrometry; opened ADME-lab in 2015), clinical diagnostics, and genetic assays. In 2014, BioCore merged with Genocheck, which specializes in genomic technologies providing customized lifetime healthcare for prenatal, newborn, pediatrics, and adults. For more information, visit www.bio-core.com.
Gwynn Ballentine, PhD MBA
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diversigen-announces-strategic-partnership-with-korea-based-biocore-300239527.html
SOURCE Diversigen, Inc.